- Home
- News
- Articles+
- Aerospace
- Agriculture
- Alternate Dispute Resolution
- Banking and Finance
- Bankruptcy
- Book Review
- Bribery & Corruption
- Commercial Litigation
- Competition Law
- Conference Reports
- Consumer Products
- Contract
- Corporate Governance
- Corporate Law
- Covid-19
- Cryptocurrency
- Cybersecurity
- Data Protection
- Defence
- Digital Economy
- E-commerce
- Employment Law
- Energy and Natural Resources
- Entertainment and Sports Law
- Environmental Law
- FDI
- Food and Beverage
- Health Care
- IBC Diaries
- Insurance Law
- Intellectual Property
- International Law
- Know the Law
- Labour Laws
- Litigation
- Litigation Funding
- Manufacturing
- Mergers & Acquisitions
- NFTs
- Privacy
- Private Equity
- Project Finance
- Real Estate
- Risk and Compliance
- Technology Media and Telecom
- Tributes
- Zoom In
- Take On Board
- In Focus
- Law & Policy and Regulation
- IP & Tech Era
- Viewpoint
- Arbitration & Mediation
- Tax
- Student Corner
- AI
- ESG
- Gaming
- Inclusion & Diversity
- Law Firms
- In-House
- Rankings
- E-Magazine
- Legal Era TV
- Events
- News
- Articles
- Aerospace
- Agriculture
- Alternate Dispute Resolution
- Banking and Finance
- Bankruptcy
- Book Review
- Bribery & Corruption
- Commercial Litigation
- Competition Law
- Conference Reports
- Consumer Products
- Contract
- Corporate Governance
- Corporate Law
- Covid-19
- Cryptocurrency
- Cybersecurity
- Data Protection
- Defence
- Digital Economy
- E-commerce
- Employment Law
- Energy and Natural Resources
- Entertainment and Sports Law
- Environmental Law
- FDI
- Food and Beverage
- Health Care
- IBC Diaries
- Insurance Law
- Intellectual Property
- International Law
- Know the Law
- Labour Laws
- Litigation
- Litigation Funding
- Manufacturing
- Mergers & Acquisitions
- NFTs
- Privacy
- Private Equity
- Project Finance
- Real Estate
- Risk and Compliance
- Technology Media and Telecom
- Tributes
- Zoom In
- Take On Board
- In Focus
- Law & Policy and Regulation
- IP & Tech Era
- Viewpoint
- Arbitration & Mediation
- Tax
- Student Corner
- AI
- ESG
- Gaming
- Inclusion & Diversity
- Law Firms
- In-House
- Rankings
- E-Magazine
- Legal Era TV
- Events
AstraZeneca Admits Rare Side Effects Of Covid-19 Vaccine Amid Legal Battle
AstraZeneca Admits Rare Side Effects Of Covid-19 Vaccine Amid Legal Battle
In a recent legal development, AstraZeneca has admitted that its Covid-19 vaccine, sold under brand names like Covishield and Vaxzevria among others may, in very rare instances, lead to severe side effects, including blood clots.
This admission comes amidst an ongoing legal battle, where AstraZeneca has for the first time admitted in court documents the potential for rare side effects associated with its Covid-19 vaccine.
The Oxford–AstraZeneca Covid vaccine, marketed globally as Covishield and Vaxzevria among others, is currently under scrutiny as the pharmaceutical company faces a class-action lawsuit. The lawsuit alleges serious injuries and deaths resulting from the vaccine, which was developed in collaboration with the University of Oxford.
Numerous families, through the court complaint, have raised concerns over the devastating effects of the AstraZeneca vaccine's side effects.
The lawsuit, initiated by Jamie Scott, who sustained a permanent brain injury after receiving the AstraZeneca vaccine in April 2021, highlights the severe impact of a rare side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS), characterized by blood clots and low platelet counts.
In legal filings submitted to the UK High Court, AstraZeneca has conceded that its vaccine "can, in very rare cases, cause TTS." This acknowledgment could potentially lead to significant compensation payouts if the company acknowledges vaccine-induced illness or death in specific cases.
However, AstraZeneca maintains its stance against claims of widespread vaccine defects or overstatement of efficacy. Despite its effectiveness in combatting the pandemic, the emergence of rare side effects has prompted regulatory scrutiny and legal action, leading to the cessation of its administration in the UK due to safety concerns.
As legal proceedings continue, affected individuals and their families seek fair compensation and acknowledgment of vaccine-induced injuries.